Klimaktoplant H in patients with acute menopausal complaints

ISRCTN	ISRCTN16340124
DOI	https://doi.org/10.1186/ISRCTN16340124
Protocol serial number	KP 004
Sponsor	Deutsche Homöopathie-Union (DHU)-Arzneimittel GmbH & Co. KG
Funder	Deutsche Homöopathie-Union (DHU)-Arzneimittel GmbH & Co. KG

Submission date: 05/04/2017
Registration date: 09/05/2017
Last edited: 12/07/2017

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Nutritional, Metabolic, Endocrine

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Background and study aims
The menopause is when a woman stops having periods and is no longer able to get pregnant naturally. This is a natural part of the aging process that usually happens when a women is around 50 years old. At this time, a woman’s oestrogen (female hormone) levels decline, leading to a range of symptoms, including hot flushes, sleep disturbances, and mood swings. There is a lot of evidence showing that the decline in oestrogen can be linked with an increased risk of heart disease and osteoporosis (brittle bones). One way of preventing this is by taking medication to replace the depleted osetrogen (hormone replacement), however this is unpopular. Klimaktoplant H is a medication used to treat menopausal symptoms without use of hormones. The aim of this study is to find out if taking Klimaktoplant H is an effective way of reducing menopausal symptoms.

Who can participate?
Women aged 40-55 years who are going through the menopause.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group take two tablets containing Klimaktoplant H three times a day for 12 weeks. Those in the second group two tablets containing a placebo (dummy drug) three times a day for 12 weeks. Over the 12 weeks of the study, participants in both groups are regularly assessed in order to find out whether the Klimaktoplant H has had any effect on menopause symptoms.

What are the possible benefits and risks of participating?
Participants who are treated with Klimaktoplant H may benefit from a reduction in their menopausal symptoms. There is a risk for those taking Klimaktoplant H of side effects, such as allergic reactions, nosebleeds, and restarting menstrual bleeding.

Where is the study run from?
Six medical practices in Kiev (Ukraine)

When is the study starting and how long is it expected to run for?
December 2000 to January 2004

Who is funding the study?
Deutsche Homöopathie-Union (DHU)-Arzneimittel GmbH & Co. KG (Germany)

Who is the main contact?
Ms Julia Burkart

Contact information

Ms Julia Burkart
Public

Deutsche Homöopathie-Union (DHU)-Arzneimittel GmbH & Co. KG
Ottostraße 24
Karlsruhe
76227
Germany

Study information

Primary study design	Interventional
Study design	Multi-centre prospective randomized double-blind placebo controlled phase III trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title	Efficacy of Klimaktoplant H in patients with acute menopausal complaints
Study objectives	The aim of this study is to evaluate the efficacy and safety of Klimaktoplant H compared to placebo in patients with acute menopausal complaints.
Ethics approval(s)	The Ethics Committee of the State Pharmacological Center of the Ministry of Health of Ukraine, 13/03/2001, ref: 5.12-91/KE
Health condition(s) or problem(s) studied	Acute menopausal complaints
Intervention	All patients meeting the entry criteria at baseline (day 0) are assigned to one of the two treatment sequences using a predetermined randomisation scheme. Intervention group: Klimaktoplant H (Cimicifuga D2, Sepia D2, Sanguinaria D2, Ignatia D3) treatment starts immediately after the baseline visit (day 0) and continues for 12 weeks. Two tablets are taken orally three times a day. There is no run-in period, where patients are monitored before they receive Klimaktoplant H. Control group: Placebo treatment startd immediately after the baseline visit (day 0) and continued for 12 weeks. Two tablets are taken orally three times a day. There is no run-in period, where patients are monitored before they receive Placebo. All patients were followed for 12 weeks in total.
Intervention type	Drug
Phase	Phase III
Drug / device / biological / vaccine name(s)	Klimaktoplant H
Primary outcome measure(s)	The efficacy of Klimaktoplant H compared to placebo, assessed as change of the total score of the Menopause Rating Scale, is measured using the Menopause Rating Scale at baseline (day 0) and 12 weeks (day 84).
Key secondary outcome measure(s)	1. Treatment outcome is measured using the Integrative Medicine Outcomes Scale (IMOS) at day 28, day 58 and day 84 rated by investigator and patients 2. Onset of the effect of investigational medication is measured by the entries in patient’s diary that is used during the treatment period 3. Health status of the patients is measured using the SF-12 Health Survey and EQ-5D questionnaire at baseline (day 0), day 28, day 58 and day 84 4. Satisfaction with treatment is measured using the Integrative Medicine Patient Satisfaction Scale (IMPSS) at day 84
Completion date	30/01/2004

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Female
Target sample size at registration	350
Key inclusion criteria	1. Age 40–55 years 2. Acute menopausal complaints in the pre-, peri- and early postmenopausal period 3. Total score of the Menopause Rating Scale ≥ 20 points and at least severe complaints concerning the symptom "hot flushes, sweating" 4. Female
Key exclusion criteria	1. Menopause is longer than 3 years ago 2. Forced indication for hormonal replacement therapy (e.g. surgical menopause, manifest osteoporosis) 3. Hormonal replacement therapy in the last 6 months before enrolment into the trial and/or treatment with herbal or homeopathic medication in the last 3 months before enrolment into the trial 4. Concomitant medications, that might impair the trial result (e.g. hormones, centrally effective antihypertensive agents, other therapies of menopausal complaints) 5. Known or supposed hypersensitivity against trial medication 6. Severe concomitant diseases, e.g. heart and liver diseases, and/or immune suppression or multimorbidity 7. Known alcohol or drug abuse 8. Have taken part in another clinical trial during the last 6 months 9. Irresponsible patients or patients unable to understand nature, meaning and consequences of the trial
Date of first enrolment	24/04/2001
Date of final enrolment	26/11/2002

Locations

Countries of recruitment

Ukraine

Study participating centres

Faculty No 1 of Obestrics and Gynecology of the National Medical University A.A. Bogomolets

Shavchenko Avenue 17
Kiev
01004
Ukraine

Pregnant consultation hour No 1 of the medical district area of Radianskiy region

Zoologicheskaya Street 3
Kiev
01004
Ukraine

Pregnant consultation hour No 3 of the medical district area of Radianskiy region

Bogdana Khmelnitskogo Street 37
Kiev
01000
Ukraine

Pregnant consultation hour No 1 of the medical district area of Leningradskiy region

Kuchera Street 7
Kiev
01000
Ukraine

Pregnant consultation hour No 3 of the 1st adult polyclinic of the medical district area of Dneprovskiy region

Petra Zaporozhtsa 17
Kiev
01000
Ukraine

Pregnant consultation hour for obestrics No 4 of the medical district of Minskiy region

Geroev Stalingrada 16
Kiev
01210
Ukraine

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not expected to be made available
IPD sharing plan	The datasets generated during and/or analysed during the current study is not expected to be made available due to ethical reasons, participant confidentiality and in terms of other data protection law.

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

Editorial Notes

12/07/2017: Internal edit.